Our History
For successful and reproducible experiments researchers need to use viable cells so they can accurately assess cell responses such as cell signals, drug toxicity and cell viability to potential drug treatments. After enduring the pain of low efficiency and high cytotoxicity first hand, and knowing that there are millions like them, our founders wanted a better way to non-virally transfect cells. This led to the WaveCyte way, taking the guess work out of non-viral cell transfection. WaveCyte Biotechnologies is a pre-clinical stage biotechnology company working with different partners to discover the next generation of best-in-class biologics with an emphasis on cell and gene therapy. WaveCyte’s platform technology, Kitaka, combines a proprietary non-viral cell transfection process with automation for high scalability, predictability and reproducibility making non-viral cell engineering easier and faster. Kitaka is gentle and highly efficient in intracellular cargo delivery resulting in higher cell viability and efficiency of even difficult to transfect cells post transfection compared to commonly used non-viral processes. Using our platform and processes, we are helping scientists navigate the challenges of accelerating their cell and gene therapy discoveries. Our platform technology and processes will help you move with speed and quality because we believe that patients are waiting for your discoveries to change their lives.
